J Med Chem. 2019 Sep 12;62(17):8152-8163. doi: 10.1021/acs.jmedchem.9b00919. Epub 2019 Aug 21.
Proteolysis targeting chimera (PROTAC) recruits an E3 ligase to a target protein to induce its ubiquitination and subsequent degradation. We reported success in the development of two PROTACs ( and ) that potently and selectively induce the degradation of Mcl-1 and Bcl-2 (DC = 0.7 and 3.0 μM), respectively, by introducing the E3 ligase cereblon-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitors and with micromolar-range affinity. -induced Mcl-1 ubiquitination translated into much more lethality in Mcl-1-dependent H23 cells than the most potent Mcl-1 occupancy-based inhibitor with nanomolar-range affinity. Moreover, structure-activity relationship analysis and molecular dynamic simulations discovered the structural basis for turning nonselective or promiscuous Bcl-2 family ligands into selective PROTACs. and exhibited reversible depletion in living cells, which provides a new potent toolkit for gain-of-function studies to probe the dynamic roles of Bcl-2 and Mcl-1 in apoptosis networks.
蛋白水解靶向嵌合体(PROTAC)招募 E3 连接酶到靶蛋白上,诱导其泛素化和随后的降解。我们成功开发了两种 PROTAC( 和 ),通过将 E3 连接酶 cereblon 结合配体泊马度胺引入到对 Mcl-1 和 Bcl-2 具有纳摩尔亲和力的双重抑制剂 和 中,分别有效地和选择性地诱导 Mcl-1 和 Bcl-2 的降解(DC = 0.7 和 3.0 μM)。 诱导的 Mcl-1 泛素化导致在依赖 Mcl-1 的 H23 细胞中的致死性比具有纳摩尔亲和力的最有效的基于 Mcl-1 占据的抑制剂 更强。此外,结构-活性关系分析和分子动力学模拟发现了将非选择性或混杂的 Bcl-2 家族配体转化为选择性 PROTAC 的结构基础。 和 在活细胞中表现出可恢复的耗竭,这为功能获得研究提供了一个新的有效工具包,以探究 Bcl-2 和 Mcl-1 在凋亡网络中的动态作用。